Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: The Pittsburgh epidemiology of diabetes complications study

Diabetic Medicine

Volumn 20, Issue 2, 2003, Pages 147-151

  Bosnyak, Z ^a   Forrest, K Y Z ^b   Maser, R E ^c   Becker, D ^d   Orchard, Trevor J ^a,e  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b SLIPPERY ROCK UNIVERSITY   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Coronary artery disease; Overt nephropathy; PAI 1; tPA PAI 1; Type 1 diabetes

Indexed keywords

FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037332051     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.00898.x     Document Type: Article

References (29)

1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
2. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
3. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med 1985; 313: 1557-1563.
4. Hamsten A, De Faire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
5. Brownlee M. Microvascular disease and related abnormalities: their relation to control of diabetes. In Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS eds. Joslin's Diabetes Mellitus. Philadelphia: Lea & Febiger, 1985: 185.
6. Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966.
7. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnel M et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994; 43: 831-835.
8. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med 1991; 8: 898-905.
9. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39: 1116-1124.
10. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990; 13: 741-747.
11. Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J. The hypertension detection and follow-up program. Prev Med 1976; 5: 207-215.
12. Orchard TJ for the CSP investigators. Validation of coronary heart disease mortality data: the Community Cardiovascular Surveillance Project Pilot Experience. Am Heart Assoc Cardiovasc Dis Epidemiol Newslett 1985; 157: 46.
13. Maser RE, Ellis D, Erbey JR, Orchard TJ. Little relationship of plasminogen activator inhibitor (PAI-1) with complications of insulin-dependent diabetes mellitus: Pittsburgh Epidemiology of Diabetes Complications study. Fibrinolysis 1995; 9: 139-144.
14. Maser RE, Ellis D, Erbey JR, Orchard TJ. Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications study. J Diab Complications 1997; 11: 243-249.
15. Almer LO, Sundkvist G, Lilja B. Fibrinolytic activity, autonomic neuropathy, and circulation in diabetes mellitus. Diabetes 1983; 32: 4-7.
16. Meade TW, Chakraberti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979; 1: 153-156.
17. Simpson AJ, Booth NA, Moore NR, Gray RS. Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus? Diabet Med 1998; 15: 683-687.
18. Almer LO, Janzon L. Low vascular fibrinolytic activity in obesity. Thromb Res 1975; 6: 171-175.
19. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987; 258: 1183-1186.
20. Folsom AR, Aleksic N, Park E, Samomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: The Atherosclerotic Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-617.
21. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-3325.
22. Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
23. Gram J, Bladbjerg E-M, Møller L, Sjøl A, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease: a nested case-control study. J Intern Med 2000; 247: 205-212.
24. Huber K, Beckmann R, Lang I, Schuster E, Binder BR. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis 1989; 3: 41-43.
25. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin dependent) diabetes mellitus. Thromb Res 1993; 71: 405-415.
26. Vague P. Insulin and the fibrinolytic system: a link between metabolism and thrombogenesis. IDF Bull 1991; 36: 15-17.
27. Phillips DK. Hypercoagulability and thrombosis: the promise of endothelial cells. Clin Lab Sci 1990; 3: 170.
28. Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 1989; 9: 934-939.
29. Nilson TK, Lithner F. Glycemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type 1 diabetic patients but microangiopathy does not. Acta Med Scand 1988; 224: 123-129.